A Baltimore-based company is utilizing the power of artificial intelligence (AI) and deep learning to advance drug discovery, biomarker development and aging research.

Leveraging advanced AI, Insilico Medicine aims to use bioinformatics, research and development to extend patient lives.

“You have to look at the number of quality years of life you’re adding. If you include every individual on the planet, and you are adding one year of quality life to each of them, you’re generating 7.5 billion quality-adjusted life years,” said founder and CEO Alex Zhavoronkov, PhD. “That is the most altruistic decision to make. So if you go after aging, you are affecting the quality of life for everyone on the planet. The benefit of aging research generates the most benefit to society as a whole. If I can personally give one year of quality life to everyone, my life was very well spent.”

Read the full story from Forbes below: